WO2022235059A1 - 폐암의 예방 또는 치료용 약학 조성물 - Google Patents
폐암의 예방 또는 치료용 약학 조성물 Download PDFInfo
- Publication number
- WO2022235059A1 WO2022235059A1 PCT/KR2022/006352 KR2022006352W WO2022235059A1 WO 2022235059 A1 WO2022235059 A1 WO 2022235059A1 KR 2022006352 W KR2022006352 W KR 2022006352W WO 2022235059 A1 WO2022235059 A1 WO 2022235059A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding
- protein
- ferritin
- pharmaceutical composition
- immune checkpoint
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 41
- 201000005202 lung cancer Diseases 0.000 title claims description 41
- 208000020816 lung neoplasm Diseases 0.000 title claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title claims description 21
- 230000002265 prevention Effects 0.000 title claims 2
- 238000009739 binding Methods 0.000 claims abstract description 87
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 59
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 57
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims abstract description 56
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims abstract description 56
- 229940126546 immune checkpoint molecule Drugs 0.000 claims abstract description 54
- 102000008857 Ferritin Human genes 0.000 claims description 95
- 108050000784 Ferritin Proteins 0.000 claims description 95
- 235000018102 proteins Nutrition 0.000 claims description 52
- 238000008416 Ferritin Methods 0.000 claims description 47
- 239000000178 monomer Substances 0.000 claims description 40
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 36
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 19
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims description 13
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 13
- -1 LIGHT Proteins 0.000 claims description 12
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 101001002987 Homo sapiens Ferritin heavy chain Proteins 0.000 claims description 8
- 102000054087 human FTH1 Human genes 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 6
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 6
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 6
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 6
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 238000001338 self-assembly Methods 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 5
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 5
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 5
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 4
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 3
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 108091012583 BCL2 Proteins 0.000 claims description 3
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims description 3
- 108091005625 BRD4 Proteins 0.000 claims description 3
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims description 3
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 claims description 3
- 102100033640 Bromodomain-containing protein 1 Human genes 0.000 claims description 3
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 claims description 3
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 claims description 3
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 102100036008 CD48 antigen Human genes 0.000 claims description 3
- 108010065524 CD52 Antigen Proteins 0.000 claims description 3
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 3
- 108091008815 Eph receptors Proteins 0.000 claims description 3
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 claims description 3
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 claims description 3
- 108091008794 FGF receptors Proteins 0.000 claims description 3
- 102100031351 Galectin-9 Human genes 0.000 claims description 3
- 101710121810 Galectin-9 Proteins 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims description 3
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 claims description 3
- 101000871846 Homo sapiens Bromodomain-containing protein 1 Proteins 0.000 claims description 3
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 claims description 3
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 3
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 3
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims description 3
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 3
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 3
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims description 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 3
- 101000742054 Homo sapiens Protein phosphatase 1D Proteins 0.000 claims description 3
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 claims description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims description 3
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 3
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims description 3
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 3
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 3
- 102100038675 Protein phosphatase 1D Human genes 0.000 claims description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 3
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 claims description 3
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 102100024026 Transcription factor E2F1 Human genes 0.000 claims description 3
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 3
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 3
- 102000034238 globular proteins Human genes 0.000 claims description 3
- 108091005896 globular proteins Proteins 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 108010048507 poliovirus receptor Proteins 0.000 claims description 3
- 239000004474 valine Chemical group 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 68
- 206010028980 Neoplasm Diseases 0.000 description 62
- 201000011510 cancer Diseases 0.000 description 47
- 239000000872 buffer Substances 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 210000000822 natural killer cell Anatomy 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 101000894590 Homo sapiens Uncharacterized protein C20orf85 Proteins 0.000 description 12
- 102100021442 Uncharacterized protein C20orf85 Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 238000002619 cancer immunotherapy Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940066453 tecentriq Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000000546 Apoferritins Human genes 0.000 description 2
- 108010002084 Apoferritins Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102220480600 Dimethylglycine dehydrogenase, mitochondrial_R23A_mutation Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102220575187 Egl nine homolog 1_F82A_mutation Human genes 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102220640571 Regulatory-associated protein of mTOR_Q84A_mutation Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102220549987 Usher syndrome type-1C protein-binding protein 1_Q15A_mutation Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229950001573 abemaciclib Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 229960001611 alectinib Drugs 0.000 description 2
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960001292 cabozantinib Drugs 0.000 description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229960002465 dabrafenib Drugs 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229960000439 eribulin mesylate Drugs 0.000 description 2
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102200097286 rs199472825 Human genes 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102220505885 Borealin_D124A_mutation Human genes 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102220476524 Interleukin-18_K120A_mutation Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229950009579 axicabtagene ciloleucel Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 229940126533 immune checkpoint blocker Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical group ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102220005491 rs35932809 Human genes 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229950007137 tisagenlecleucel Drugs 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960001183 venetoclax Drugs 0.000 description 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a pharmaceutical composition for preventing or treating lung cancer.
- cancer requires a very difficult and complex treatment.
- the methods currently used for cancer treatment include surgery, radiation therapy, and chemotherapy. If the cancer has not metastasized to other sites and is localized, cancer can be treated through surgery to remove the cancer. However, since cancer metastasis occurs in more than 70% of cancer patients, adjuvant treatment regimens must be combined.
- the adjuvant treatment therapies radiation therapy to kill cancer cells is performed using high-energy radiation.
- the proliferation of cancer cells is inhibited when the cancer cells are irradiated with radiation, so that new cancer cells cannot be generated and cancer cells. prevent further division.
- this method has a problem in that there is a side effect that affects not only cancer cells but also normal cells.
- Chemotherapy is an adjuvant treatment that uses drugs to kill cancer cells after surgery with the aim of killing invisible cancer cells.
- the chemotherapy has a problem in that side effects such as vomiting, diarrhea, and hair loss follow.
- Immunotherapy is a method of treating cancer using the patient's immune response, and can even prevent cancer.
- Cancer immunotherapy like the principle of a vaccine, is a treatment method in which cancer-specific immune cells are activated by administering an antigen that causes tumor formation, and then the activated immune cells specifically attack cancer in the body.
- cancer-specific antigen is administered into the body even if the patient does not have cancer.
- the inactivated immune cells are activated as cancer-specific memory immune cells to specifically attack cancer cells when cancer occurs.
- cancer-specific antigens Tumor-associated antigen
- TAA Tumor-associated antigen
- TSA Tumor-specific antigen
- neo-antigens which are found in various tumor types such as lung cancer and kidney cancer, but mainly found in lung cancer and melanoma, are antigens newly generated by potential gene activity or DNA mutations in cancer patients. Therefore, this antigen is very important in the production of a 'customized cancer vaccine' based on the patient's individual genetic information.
- Non-Patent Document 1 Polymers are widely used as carriers of cancer-specific antigens in the body, and when cancer antigens are immobilized on the surface of polymers for delivery of cancer-specific antigens in the body, the cancer-specific antigens must be exposed to the particle surface through chemical bonding. . However, there is still a limit in the portion for uniformly exposing the cancer-specific antigen to the particle surface at a high density.
- cancer immunotherapy Compared to conventional anticancer treatment methods, cancer immunotherapy has low side effects because it uses the patient's immune system, and the therapeutic effect can last for a long time by forming immune memory. It has the advantage of having few side effects. In addition, due to the recent clinical success cases of cancer patients with recurrent or anticancer drug resistance, cancer immunotherapy is receiving explosive attention enough to be selected as Breakthrough of the year 2013 by Science.
- An object of the present invention is to provide a pharmaceutical composition for preventing or treating lung cancer comprising a protein capable of binding to an immune checkpoint molecule.
- An object of the present invention is to provide a method for treating lung cancer using the above composition.
- the present invention provides a pharmaceutical composition for preventing or treating lung cancer comprising a ferritin protein in which a molecule capable of binding to an immune checkpoint molecule is fused to an external surface.
- the protein may be a spherical protein formed by self-assembly of 24 ferritin monomers fused with a molecule capable of binding to the immune checkpoint molecule.
- a molecule capable of binding an immune checkpoint molecule may be fused to at least one of the interior of at least one of the ⁇ -helices of the ferritin monomer or between adjacent ⁇ -helices.
- Molecules capable of binding an immune checkpoint molecule may be fused to the N-terminus or C-terminus of the ferritin monomer.
- Molecules capable of binding an immune checkpoint molecule may be fused inside the A helix, B helix, C helix, D helix or E helix of the ferritin monomer.
- Molecules capable of binding immune checkpoint molecules may be fused to loops A-B, loop B-C, loop C-D or loop D-E of the ferritin monomer.
- the molecule capable of binding to the immune checkpoint molecule may be fused between the N-terminus and the A helix or between the E helix and the C-terminus of the ferritin monomer.
- the protein may be mutated so that binding to the human transferrin receptor is reduced.
- the protein may be one in which amino acids 15, 16, 23, 82, 84, 117, 120 or 124 in the sequence of SEQ ID NO: 1 are substituted with alanine, glycine, valine or leucine.
- the ferritin protein may have a binding affinity (K) to the transferrin receptor, satisfying Equation 1 below:
- the binding ability to the transferrin receptor may be binding to the human transferrin receptor.
- the immune checkpoint molecules are Her-2/neu, VISTA, 4-1BBL, Galectin-9, Adenosine A2a receptor, CD80, CD86, ICOS, ICOSL, BTLA, OX-40L, CD155, BCL2, MYC, PP2A, BRD1, BRD2 , BRD3, BRD4, BRDT, CBP, E2F1, MDM2, MDMX, PPP2CA, PPM1D, STAT3, IDH1, PD1, CTLA4, PD-L1, PD-L2, LAG3, TIM3, TIGIT, BTLA, SLAMF7, 4-1BB, OX -40, ICOS, GITR, ICAM-1, BAFFR, HVEM, LFA-1, LIGHT, NKG2C, SLAMF7, NKp80, LAIR1, 2B4, CD2, CD3, CD16, CD20, CD27, CD28, CD40L, CD48, CD52, EGFR It may be any one selected from the group consisting of
- the molecule capable of binding to the immune checkpoint molecule may be a ligand or a fragment of a ligand having binding affinity to the immune checkpoint molecule, a receptor or a fragment of a receptor, an antibody or an antibody fragment including an antigen binding region (CDR).
- CDR antigen binding region
- the ferritin may be a human ferritin heavy chain.
- the ferritin protein may be present in an aqueous fraction of 40% or more in the E. coli production system.
- the protein of the present invention has excellent binding ability to immune checkpoint molecules.
- the protein of the present invention enables T cells to kill cancer cells by preventing immune checkpoint molecules from inactivating T cells.
- the proteins of the invention can fuse molecules that bind to a variety of immune checkpoint molecules.
- the protein of the present invention is capable of binding to various immune checkpoint molecules.
- the pharmaceutical composition for preventing or treating cancer of the present invention has excellent anticancer efficacy.
- FIG. 1 is a schematic diagram of a basic vector for preparing wild type (native) human ferritin heavy chain (huHF) and mutant human ferritin heavy chain protein.
- FIG. 2 is a schematic diagram of a vector for producing huHF_Mutant1-dual and a view confirming the production of the ferritin protein.
- FIG. 3 is a schematic diagram of a vector for producing huHF_Mutant1-h_smPD1 and a diagram confirming the production of the ferritin protein.
- 11 is a result of evaluation of binding affinity to human transferrin receptor of huHF_Mutant1-dual and huHF_Mutant2-dual.
- 13 and 14 are results of evaluation of binding ability between NK cells and cancer cells according to huHF_mutant1-dual treatment.
- 16 is a schematic diagram of the LLC1 lung cancer animal model preparation and tumor suppression experiment.
- 17 and 18 are tumor growth inhibition evaluation results according to huHF_mutant1-dual treatment.
- 19 to 21 are avidity evaluation results for the lung cancer cell line A549 of huHF_mutant1-dual.
- 22 is an evaluation result of tumor growth inhibition in an animal model of LLC1 lung cancer when huHF_mutant1-dual or a combination thereof with an anticancer agent is used.
- 23 and 24 show a schematic diagram of a vector for producing a ferritin protein in which a foreign peptide is fused to a helix and protein production results.
- the present invention relates to a pharmaceutical composition for preventing or treating lung cancer, comprising a ferritin protein fused with an immune checkpoint molecule and a molecule capable of binding to an external surface thereof.
- Ferritin may be ferritin from humans, animals and microorganisms.
- Human ferritin is composed of a heavy chain (21 kDa) and a light chain (19 kDa), and exhibits the property of forming spherical nanoparticles through the self-assembly ability of the monomers constituting the ferritin.
- Ferritin can form a self-assembly having a spherical three-dimensional structure by gathering 24 monomers.
- the outer diameter is about 12 nm and the inner diameter is about 8 nm.
- the structure of the ferritin monomer is a form in which five ⁇ -helix structures, namely, A helix, B helix, C helix, D helix, and E helix, are sequentially connected, and each ⁇ -helix structure called a loop consists of a polypeptide. It contains a portion of the atypical polypeptide to which it is linked.
- the loop is a region that is not structurally broken even when a peptide or a small protein antigen is inserted into ferritin.
- a peptide-ferritin fusion protein monomer in which a peptide such as an epitope is located in a ferritin monomer can be prepared.
- the loop connecting the helix A and the helix B is A-B loop
- the loop connecting the helix B and helix C is loop B-C
- the loop connecting the helix C and helix D is C-D loop
- the loop connecting the helix D and E is D-E. called loop.
- the ferritin may be a ferritin heavy chain, specifically, a human ferritin heavy chain.
- the human ferritin heavy chain may be a protein represented by the amino acid sequence of SEQ ID NO: 1 derived from humans, and in the present specification, the ferritin may be used interchangeably with 'human ferritin heavy chain' or 'huHF'.
- the ferritin protein may be a ferritin monomer. Accordingly, it may be a ferritin heavy chain monomer or a human ferritin heavy chain monomer.
- Ferritin self-assembles several of its monomers to form an organized structure or pattern.
- the ferritin protein of the present invention is a nanoscale particle.
- 24 ferritin monomers fused with a molecule capable of binding to an immune checkpoint molecule may be self-assembled to form a ferritin protein.
- the ferritin protein may be globular.
- the particle diameter may be 8 to 50 nm. More specifically, it may be 8 nm to 50 nm, 8 nm to 45 nm, 8 nm to 40 nm, 8 nm to 35 nm, 8 nm to 30 nm, 8 nm to 25 nm, 8 nm to 20 nm, and 8 nm to 15 nm.
- the ferritin protein is a fusion of a molecule capable of binding to an immune checkpoint molecule on an external surface. As long as the molecule capable of binding to the immune checkpoint molecule is fused to the outer surface of the ferritin protein, it is not necessary that the molecule capable of binding the immune checkpoint molecule is fused to all ferritin monomers constituting the ferritin protein.
- a molecule capable of binding an immune checkpoint molecule may be fused to at least one ferritin monomer among the 24 ferritin monomers.
- all 24 ferritin monomers can be fused with molecules capable of binding to immune checkpoint molecules.
- One or two or more types of molecules capable of binding to an immune checkpoint molecule may be fused to each ferritin monomer constituting the ferritin protein.
- Each ferritin monomer constituting the ferritin protein may be fused with molecules capable of binding to different immune checkpoint molecules.
- Each ferritin monomer constituting the ferritin protein may be fused with different molecules capable of binding to the same immune checkpoint molecule.
- Immune checkpoint molecules bind to T cells and inactivate them.
- Such immune checkpoint molecules include, for example, Her-2/neu, VISTA, 4-1BBL, Galectin-9, Adenosine A2a receptor, CD80, CD86, ICOS, ICOSL, BTLA, OX-40L, CD155, BCL2, MYC, PP2A, BRD1, BRD2, BRD3, BRD4, BRDT, CBP, E2F1, MDM2, MDMX, PPP2CA, PPM1D, STAT3, IDH1, PD1, CTLA4, PD-L1, PD-L2, LAG3, TIM3, TIGIT, BTLA, SLAMF7, 4- 1BB, OX-40, ICOS, GITR, ICAM-1, BAFFR, HVEM, LFA-1, LIGHT, NKG2C, SLAMF7, NKp80, LAIR1, 2B4, CD2, CD3, CD16, CD20, CD27, CD28, CD40L, CD48
- the molecule capable of binding to the immune checkpoint molecule may be a ligand or a fragment of a ligand having binding affinity to the immune checkpoint molecule, a receptor or a fragment of a receptor, an antibody or a fragment of an antibody comprising an antigen binding site (CDR).
- CDR antigen binding site
- Molecules capable of binding immune checkpoint molecules may be fused to any ferritin monomer as long as they can be exposed on the outer surface of the ferritin protein. Molecules capable of binding to immune checkpoint molecules are fused at positions that do not interfere with self-assembly of ferritin monomers.
- Molecules capable of binding to immune checkpoint molecules can be fused inside the ferritin monomer to change the structure of the ferritin protein.
- the internally indented part may protrude to the outside by fusion of molecules capable of binding to the immune checkpoint molecule. It can be incorporated into the interior by fusion of a molecule capable of binding with the .
- the molecule capable of binding to the immune checkpoint molecule is preferably fused to a position where the ferritin protein reduces binding to the human transferrin receptor or interferes with the binding to the human transferrin receptor.
- a molecule capable of binding to an immune checkpoint molecule is not limited to a specific range in its structure, molecular weight, and amino acid length.
- a molecule capable of binding an immune checkpoint molecule may be, for example, a ligand, antibody, or fragment thereof whose amino acid length is 25aa or less. More specifically, the amino acid length is 25aa or less, 24aa or less, 23aa or less, 22aa or less, 21aa or less, 20aa or less, 19aa or less, 18aa or less, 17aa or less, 16aa or less, 15aa or less, 14aa or less, 13aa or less, 12aa or less, 11aa or less or less, 10aa or less, 9aa or less, 8aa or less, 7aa or less, 6aa or less, 5aa or less.
- the amino acid may have a length of 3aa or more, 4aa or more, 5aa or more, 6aa or more, 7aa or more, 8aa or more, 9aa or more, 10aa or more.
- the fusion site of the molecule capable of binding with the immune checkpoint molecule is not limited to a specific position, for example, inside the ⁇ -helix of the ferritin monomer (A helix, B helix, C helix, D helix, or E helix), between adjacent ⁇ -helices. , N-terminus, C-terminus, A-B loop, B-C loop, C-D loop, D-E loop, between N-terminus and A helix, between E helix and C-terminus, inside helix, and the like.
- the protein of the present invention is a ferritin monomer within the ⁇ -helix (A helix, B helix, C helix, D helix, or E helix), between adjacent ⁇ -helices, N-terminal, C-terminal, A-B loop, It may further include a foreign peptide fused to the B-C loop, C-D loop, D-E loop, between the N-terminus and the A helix, between the E helix and the C-terminus, inside the helix, and the like.
- the foreign peptide may be a pharmacologically active peptide.
- the ferritin protein is designed to bind to an immune checkpoint molecule, it is preferable that it does not bind well to the transferrin receptor.
- the ferritin protein satisfies the following Equation 1 for the transferrin receptor:
- the binding force may be, for example, binding to the human transferrin receptor.
- the K value of Equation 1 is 10 nM or more, 20 nM or more, 30 nM or more, 40 nM or more, 50 nM or more, 60 nM or more, 70 nM or more, 80 nM or more, 90 nM or more, 100 nM or more, 110 nM or more, 120 nM or more, 125 nM or more, 125 nM or more, 150 nM or more, 200nM or more, 210nM or more, 220nM or more, 230nM or more, 240nM or more, 250nM or more, 260nM or more, 270nM or more, 280nM or more, 290nM or more, 300nM or more, 350nM or more, 400nM or more, 450nM or more, 500nM or more, 550nM or more, 600 nM or more, 700 nM or more, 800 nM or more, 900 nM or more, 1000 nM
- the upper limit may be, for example, 100000nM, 90000nM, 80000nM, 70000nM, 60000nM, 50000nM, 10000nM, 9000nM, 8000nM, 7000nM, 6000nM, 5000nM, etc., but is not limited thereto.
- the binding force (K) to the transferrin receptor is measured in the equilibrium state of the binding reaction between the ferritin protein (A) of the present invention and the transferrin receptor.
- concentration of the ferritin protein at equilibrium ([P]), the concentration of the transferrin receptor ([T]), and the concentration of the complex of the protein of the present invention and the transferrin receptor ([PT]) can be measured by various known methods. .
- the ferritin protein may fuse a molecule capable of binding with an immune checkpoint molecule to a site involved in binding to the transferrin receptor in order to lower the binding force to the transferrin receptor.
- the molecule capable of binding to an immune checkpoint molecule may be fused to the B-C loop and the A helix portion of the ferritin protein of the present invention.
- the ferritin protein may be mutated so that binding to the human transferrin receptor is reduced.
- amino acids 15, 16, 23, 82, 84, 117, 120 or 124 in the sequence of SEQ ID NO: 1 may be substituted with alanine, glycine, valine or leucine.
- the ferritin protein may be produced in a microorganism expressing a sequence encoding the protein.
- Microorganisms known in the art may be used without limitation.
- it may be E. coli, specifically BL21 (DE3), but is not limited thereto.
- the ferritin protein of the present invention has a high rate of lysis in the cytoplasm in the microbial production system. It is easy to separate/purify and utilize.
- the ferritin protein may be prepared, for example, in an E. coli system for producing it in a state in which the water-soluble fraction ratio of the total protein is 40% or more. Specifically, it may be 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more.
- the upper limit may be, for example, 100%, 99%, 98%, 97%, 96%, or the like.
- the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier refers to a carrier or diluent that does not significantly stimulate the organism and does not inhibit the biological activity and properties of the administered component.
- the pharmaceutically acceptable carrier in the present invention can be used by mixing one component or one or more components among saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and these components, Other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary to form an injection suitable for injection into tissues or organs.
- a target organ-specific antibody or other ligand may be used in combination with the carrier so as to act specifically on the target organ.
- composition of the present invention may further include a filler, an excipient, a disintegrant, a binder or a lubricant.
- compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the pharmaceutical composition may be an injection formulation, and may be administered intravenously, but is not limited thereto.
- the term “effective amount” refers to an amount necessary to delay the onset or progression of a specific disease to be treated or to promote it entirely.
- the composition may be administered in a pharmaceutically effective amount. It is apparent to those skilled in the art that a suitable total daily amount of the pharmaceutical composition can be determined by a treating physician within the scope of sound medical judgment.
- a specific pharmaceutically effective amount for a specific patient is the specific composition, including the type and extent of the response to be achieved, whether or not other agents are used if necessary, the patient's age, weight, general health status, sex It is preferable to apply differently depending on various factors including diet, administration time, administration route and secretion rate of the composition, treatment period, drugs used together or concurrently with a specific composition, and similar factors well known in the pharmaceutical field.
- the pharmaceutical composition may be accompanied by instructions associated with packaging in a form instructed by a government agency in charge of the manufacture, use and sale of drugs, if necessary, and the instructions are in the form of a composition or human or human. It indicates the approval of a private interest organization for administration to animals, and may be, for example, a label approved by the US Food and Drug Administration for the prescription of a drug.
- the pharmaceutical composition of the present invention may further include an anticancer agent, or may be administered in combination with an anticancer agent.
- anticancer agent any substance having anticancer activity may be used without limitation, and known anticancer agents may also be used.
- the anti-cancer agent may be a chemo-cancer agent, a targeted anti-cancer agent, or an immuno-cancer agent.
- the chemotherapy is not limited thereto, but may be an alkylating agent, a microtuble inhibitor, an antimetbolite, or a topoisomerase inhibitor.
- the alkylating agent is mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine ), procarbazine, busulfan, streptozocin, carmustine, iomustine, dacarbazine, cisplatin, carboplatin ( carboplatin), but may be oxaliplatin (oxaliplatin), but is not limited thereto.
- the microtubule inhibitor may be docetaxel (docetaxel), vinblastine (vinblastine), oncobin (Oncovin), vinorelbine (vinorelbine), but is not limited thereto.
- the antagonist is fluorouracil, capecitabine, cytarabine, gemcitabine, fludarabine, methotrexate, pemetrexed, It may be mercaptopurine (mercaptopurine), but is not limited thereto.
- the topoisomerase inhibitor may be hycamtin, camptosar, vepesid, taxol, bleomycin, adriamycin, or cerubidine. , but not limited thereto.
- Targeted anticancer agents include, but are not limited to, trastuzumab, pertuzumab, panitumumab, cetuximab, bevacizumab, ramucirumab, aflibercept, rituximab, obinutuzumab, daratumumab, denosumab, ibrutinib, dasatinib, Nilotinib, imatinib, bosutinib, osimertinib, erlotinib, gefitinib, nintedanib, sunitinib , sorafenib, cabozantinib, lenvatinib, regorafenib, axitinib, pazopanib, cabozantinib, tra Metinib (trametinib), dabrafenib (dabrafenib), abemaciclib (abemac
- the immuno-cancer agent is not limited thereto, but may be an immune checkpoint inhibitor, an immune cell therapeutic agent (CAR-T), an antibody drug conjugate (ADC), a dual antibody, an anti-cancer virus, or an anti-cancer vaccine.
- CAR-T immune cell therapeutic agent
- ADC antibody drug conjugate
- the checkpoint inhibitor may be a PD-1 antibody, a PD-L1 antibody, a CTLA-4 antibody, a TIM3 antibody, or a LAG3 antibody.
- the PD-1 antibody may be pembrolizumab, nivolumab, or cemiplimab
- the PD-L1 antibody is atezolizumab, avelumab, or durvallu. It may be durvalumab, but is not limited thereto.
- the CTLA-4 antibody may be ipilimumab or tremelimumab
- the TIM3 antibody may be MBG452
- the LAG3 antibody may be BMS-986016 or LAG525, but is not limited thereto.
- the immune cell therapeutic agent may be tisagenlecleucel or axicabtagene ciloleucel, but is not limited thereto.
- the ADC is gemtuzumab-ozogamicin, brentuximab vedotin, trastuzumab emtansine, inotuzumab ozogamicin, eribulin mesylate ( eribulin mesylate), but is not limited thereto.
- the double antibody may be blinatumomab
- the anticancer virus may be talimogene laherparepvec
- the anticancer vaccine may be sipuleucel-T,
- the present invention is not limited thereto.
- the anticancer agent may be an anticancer agent for lung cancer.
- the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered simultaneously, separately or sequentially with a conventional anticancer agent. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, and can be easily determined by those skilled in the art.
- the present invention provides a method for treating lung cancer using the above ferritin protein. All of the above descriptions regarding the ferritin protein apply as it is to the ferritin protein as an active ingredient in the cancer treatment method of the present application.
- the treatment method of the present invention comprises administering the ferritin protein of the present invention to a subject suffering from lung cancer.
- the individual suffering from lung cancer may be an animal suffering from lung cancer, specifically, a mammal suffering from lung cancer, and more specifically, a human suffering from lung cancer.
- the protein may be administered in a therapeutically effective amount.
- the term "administration” means introducing the composition of the present invention to a patient by any suitable method, and the administration route of the composition of the present invention is through various routes, either oral or parenteral, as long as it can reach the target tissue. may be administered.
- Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration or rectal administration may be administered, but is not limited thereto.
- the method of the present invention may further comprise administering an anticancer agent to the subject.
- any substance having anticancer activity may be used without limitation, for example, the anticancer agent exemplified above may be used.
- the anticancer agent may be administered simultaneously, separately or sequentially with the ferritin protein.
- huHF is a globular protein nanoparticle (12 nm) composed of 24 monomers, each of which is composed of a total of 5 ⁇ -helix.
- the present inventors induce mutations in the amino acid sequence that binds to the transferrin receptor of the huHF monomer through gene cloning, so that huHF_Mutant1 (Q15A, D16A, R23A, F82A, Q84A), huHF_Mutant2 (Q15A, D16A, R23A, F82A, Q84A, E117A, K120A, D124A) were obtained.
- the antibody CDR3 peptide and domain were inserted through gene cloning into the loop between the ⁇ -helix of huHF_Mutant1 and 2 (BC loop in huHF 5T to 176G; 92D/93W based on the PDB 3AJO sequence; 92D/93W) and the C-terminus to secure the delivery system. .
- E. coli strain BL21 [(fhuA2 [lon] ompT gal [dcm] ⁇ hsdS)] was transformed with the expression vector prepared above, respectively, and kanamycin-resistant transformants were selected.
- Transformed E. coli was cultured in flasks (250 mL Erlenmeyer flasks, 37 °C, 150 rpm) containing 50 mL of Luria-Bertani (LB) medium (containing 100 mg L-1 kanamycin). When the medium turbidity (OD 600) reached about 0.5-0.7, Isopropyl- ⁇ -Dthiogalactopyanosid (IPTG) (1.0 mM) was injected to induce expression of the recombinant gene.
- LB Luria-Bertani
- the cultured E. coli was centrifuged at 4,500 rpm for 10 minutes to recover the cell precipitate and suspended in 5 ml of a disruption solution (10 mM Tris-HCl buffer, pH 7.5, 10 mM EDTA). and crushed using an ultrasonic crusher (Branson Ultrasonics Corp., Danbury, CT, USA). After crushing, centrifugation was performed at 13,000 rpm for 10 minutes to separate the supernatant and insoluble aggregates. The separated supernatant was used for subsequent experiments.
- the supernatant obtained in Example 2 was purified through a three-step process. First, 1) Ni 2+ -NTA affinity chromatography using the binding of histidine and nickel fused to the recombinant protein was performed, 2) the recombinant protein was concentrated and a fluorescent substance was attached through buffer exchange, and 3) finally fluorescence was performed. In order to separate only the self-assembled protein nanoparticles to which the material is attached, sucrose gradient ultracentrifugation was performed. The detailed description of each step is as follows.
- E. coli cultured in the same manner as specified above was recovered, the cell pellet was resuspended in 5 mL lysis buffer (pH 8.0, 50 mM sodium phosphate, 300 mM NaCl, 20 mM imidazole), and a sonicator was used to disrupt cells.
- the lysed cell solution was centrifuged at 13,000 rpm for 10 minutes to separate only the supernatant, and then each recombinant protein was separated using a Ni 2+ -NTA column (Qiagen, Hilden, Germany) (washing buffer: pH 8.0, 50 mM).
- sodium phosphate, 300 mM NaCl, 80 mM imidazole / elution buffer pH 8.0, 50 mM sodium phosphate, 300 mM NaCl, 200 mM imidazole).
- huHF_Native, huHF_Mutant1-h_smPD1, and huHF_Mutant1-dual particles were subjected to Ni2 +- NTA affinity chromatography, and 3 ml of the eluted recombinant protein was placed in an ultracentrifugal filter (Amicon Ultra 100K, Millipore, Billerica, MA) at 5,000 g on the column. Centrifugation was performed at 5,000 g until 1 ml of the solution remained. After that, in order to attach the fluorescent material FITC (fluorescein isothiocyanate), the protein particles were buffer exchanged with sodium bicarbonate (0.1 M, pH 8.5) buffer, and the fluorescent material was attached at room temperature for 12 hours.
- FITC fluorescent material
- sucrose solution for each concentration is placed in an ultraclear 13.2ml tube (Beckman) from the solution with the highest concentration.
- ultra-high speed centrifugation was performed at 35,000 rpm at 4° C. for 16 hours (Ultracentrifuge L-90k, Beckman). After centrifugation, the upper layer (20-25% sucrose solution part) was carefully replaced with a pipette using an ultracentrifugal filter and PBS buffer as described in 2).
- BL21 competent cells were transformed with various expression vectors based on pCM (Tac promoter).
- a single colony was inoculated into LB liquid medium (50 mL) supplemented with 100 mg/L of kanamycin and cultured at 37° C. and 130 rpm in a shaking incubator.
- the turbidity/optical density at 600 nm reached 0.5
- the expression of the target protein was induced through administration of 1 mM IPTG.
- the cells in the culture medium were spun-down through centrifugation (13000 rpm, 10 minutes), and the cell pellet was collected and resuspended in 10 mM Tris-Hcl (pH 7.4) buffer. .
- Resuspended cells were ruptured using a Branson Sonifier (Branson Ultrasonics Corp., Danbury, CT). After sonication, the supernatant containing soluble protein and aggregates containing insoluble protein were separated by centrifugation (13000 rpm, 10 min). It was confirmed through SDS-PAGE analysis of the separated soluble and insoluble protein fractions ( FIGS. 2 and 3 ).
- TEM transmission electron microscope
- Example 3 The lung cancer cell targeting efficiencies of huHF_Native, huHF_Mutant1-h_smPD1, and huHF_Mutant1-dual proteins prepared in Example 3 to which the fluorescent material is attached were compared.
- the fluorescence intensity was measured in LLC1 mouse lung cancer and A549 human lung cancer cells. After reacting the protein at a concentration of 1400 for 2 hours, the fluorescence signal was compared to confirm the lung cancer cell targeting efficiency ( FIGS. 4 and 5 ). It was confirmed that the antibody showed significantly higher targeting efficiency than the antibody.
- huHF_Native huHF_Mutant1-h_smPD1, and huHF_Mutant1-dual proteins prepared in Example 3 against LLC1 mouse lung cancer and A549 human lung cancer
- LLC1 mouse lung cancer and A549 human lung cancer cells were incubated with proteins at a certain concentration interval for 2 hours. After the reaction, the fluorescence antibody binding to the His tag of the protein was reacted for 1 hour, and the fluorescence signal was compared to confirm the targeting efficiency ( FIGS. 5 and 6 ).
- the concentration of 50% cell fraction can be considered as Kd, and it was confirmed that it exhibited a 50-fold or more good targeting ability compared to the antibody (Table 4).
- 11 is an evaluation/comparison of the binding force of huHF_mutant1-dual and huHF_mutant2-dual to hTfR. Referring to this, in the case of huHF_mutant2-dual, even when the concentration was increased to 10000 nM, it was not saturated, indicating that the binding force to hTfR was further reduced. can be checked If the expected saturation point is selected and the binding force Kd value is calculated, it will be about 4400 nM.
- A549 a human lung cancer cell line, was labeled with CFSE, a fluorescent substance. 10 6 cells were reacted with CFSE at a concentration of 5 ⁇ M in an incubator at 37° C. for 20 minutes, washed with PBS, and cultured for one day by diluting 10 5 cells in 2 ml culture media in a 2 ml cell plate.
- NK cells were labeled using an NK 1.1 antibody-PE antibody.
- A549 a human lung cancer cell line, was labeled with CFSE, a fluorescent substance. 10 6 cells were reacted with CFSE at a concentration of 5 ⁇ M in an incubator at 37° C. for 20 minutes, washed with PBS, and cultured for one day by diluting 10 4 cells in 200 ⁇ l culture media in a 96 well plate.
- the reaction solution was reacted in an incubator for 30 minutes, and then the ratio of cells exhibiting CFSE fluorescence and DAPI fluorescence was analyzed with FACS equipment (FIG. 14). Referring to this, it can be confirmed that the binding ability of NK cells to A549 cells is increased during huHF_mutant1-dual treatment.
- NK cells were labeled with the NK 1.1 antibody-PE antibody.
- reaction solution was reacted in an incubator for 48 hours, and the toxicity ability according to the sample was verified with FACS equipment. The degree of cell death was analyzed with 7-AAD.
- the ratio of NK cells to cancer cells and the toxic ability of NK cells according to the sample were analyzed ( FIG. 15 ). Referring to this, it can be confirmed that the apoptosis ability of A549 cells of NK cells is increased during huHF_mutant1-dual treatment.
- Tecentriq is a monoclonal antibody that binds to PD-1 or PD-L1 used for the treatment of lung cancer, etc.
- mAb-mTIGIT is a monoclonal antibody that binds to murine TIGIT.
- a tumor model was formed by subcutaneously transplanting LLC1 into C57BL/6 by 5*10 5 each.
- the tumor size was measured and classified for each individual, and the same size was adjusted for each group.
- the sample was intravenously injected through the caudal vein every 3 days, and the tumor size was measured for each individual to compare the tumor growth inhibition efficacy (FIG. 16).
- FIG. 17 shows the tumor size by date in each experimental group, and FIG. 17 shows the tumor size on day 22 in each experimental group. Referring to this, in the case of huHF_mutant-dual, it can be confirmed that the effect is excellent because the tumor size is the smallest despite treatment with a smaller dose.
- target cells immunodeficiency cells, cancer cells
- the sample drug, antibody (anti-mouse PD-L1 antibody (BE0101), anti-mouse TIGIT antibody (BE0274), anti-human PD-L1 (BE0285))
- the control group 100 ⁇ l of FACS buffer (0.1%BSA + 0.01% sodium azide in PBS) was treated (3hr, room temperature).
- Fluorescence antibody (anti his tag antibody-PE(SC-8036PE), anti-IgG antibody-PE(PE goat F(ab')2 anti-rat (IgG) secondary antibody(ab7010), PE F(ab')2) -goat anti-mouse IgG (H+L) secondary antibody (12-4010-82)) was treated (2 hr, room temperature).
- a tumor model was formed by subcutaneously transplanting LLC1 into C57BL/6 by 5*10 5 each.
- the sample was intravenously injected through the caudal vein every 3 days (in the case of the G2 group, every 6 days), and the tumor size was measured for each individual to compare the tumor growth inhibition efficacy (FIG. 22).
- Ab-1 was injected at a concentration of 30 nmol/kg, huHF_mutant-dual was 30 nmol/kg, and Vac was 10 nmol/kg.
- the huHF_mutant-dual treatment group has excellent tumor growth inhibition ability, and exhibits a more excellent effect when combined with a vaccine.
- An expression vector for protein production was constructed in the same manner as in Example 1, except that the vector schematic diagrams in FIGS. 23 and 24 were used, and proteins were biosynthesized and purified by the methods described in Examples 2 and 3.
- the huHF structure is smoothly formed even when a foreign peptide is inserted (fusion) in the middle of the D helix and in the middle of the E helix as well as the loop between the A-E helix of huHF.
- BL21 (DE3) competent cells were transformed with various pT7-7-based expression vectors.
- a single colony was inoculated in LB liquid medium (50 mL) to which 100 mg/L of ampicillin was added and cultured at 37°C and 130 rpm in a shaking incubator.
- the turbidity/optical density at 600 nm reached 0.5
- the expression of the target protein was induced through administration of 1 mM IPTG.
- the cells in the culture medium were spun-down through centrifugation (13000 rpm, 10 minutes), and the cell pellet was collected and resuspended in 10 mM Tris-Hcl (pH 7.4) buffer. .
- Resuspended cells were ruptured using a Branson Sonifier (Branson Ultrasonics Corp., Danbury, CT). After sonication, the supernatant containing soluble protein and aggregates containing insoluble protein were separated by centrifugation (13000 rpm, 10 min). Solubility was analyzed by SDS-PAGE analysis of the separated soluble and insoluble protein fractions. That is, the target protein bands stained with Coomassie were scanned with a densitometer (Duoscan T1200, Bio-Rad, Hercules, CA) to quantify the proportion of soluble fractions. Specifically, using the scanned SDS-PAGE gel image, 'Quantity One' program 'Volume Rect. After setting the band thickness and background value with 'Tool', the sum of soluble and insoluble protein fractions was set to 100% using 'Volume Analysis Report' and solubility was quantified.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
명칭 | 서열번호 |
huHF_Native | 1 |
huHF-Mutant1 | 2 |
huHF-Mutant2 | 3 |
명칭 | 서열번호 |
huHF-αPD-L1 | 4 |
huHF αTIGIT | 5 |
huHF-h_smPD1 | 6 |
Linker1 | 7 |
Linker2 | 8 |
Linker3 | 9 |
단백질 | 발현 벡터 |
huHF_Native | NH2-NdeI-huHF-αPD-L1 HCDR3-HindIII-COOH |
huHF_Mutant1-dual | BC(92D/93W): NH2-NdeI-huHF_Mutant1-[αPD-L1 HCDR3]- huHF_Mutant1- αTIGIT HCDR3-HindIII-COOH |
huHF_Mutant2-dual | BC(92D/93W): NH2-NdeI-huHF_Mutant2-[αPD-L1 HCDR3]-huHF- αTIGIT HCDR3-HindIII-COOH |
huHF_Mutant1-h_smPD1 | NH2-NdeI-huHF_Mutant1-Linker2-h_smPD1-HindIII-COOH |
구분 | 표적능 | |
antibody | Human | 889~2223 |
Mouse | 985~2463 | |
huHF_Mutant1-dual | Human | 44~89 |
Mouse | 46~93 |
구분 | 결합력 | |
huHF-h_smPD1 | Native | 46.8 |
Mutant | 94.2 | |
huHF-mutant1-dual | 181.9 |
Protein NP | Solubility (%) |
intD-gp100-huHF | 48.21 |
intE-gp100-huHF | 73.00 |
Claims (16)
- 외부 표면에 면역 관문 분자와 결합 가능한 분자가 융합된 페리틴 단백질을 포함하는 폐암의 예방 또는 치료용 약학 조성물.
- 청구항 1에 있어서, 상기 단백질은 면역 관문 분자와 결합 가능한 분자가 융합된 페리틴 단량체 24개가 자기 조립되어 이루어진 구형 단백질인 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자와 결합 가능한 분자는 페리틴 단량체의 인접한 α-헬릭스들 사이 중 적어도 하나에 융합되는 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자와 결합 가능한 분자는 페리틴 단량체의 N-말단 또는 C-말단에 융합되는 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자와 결합 가능한 분자는 페리틴 단량체의 A-B루프, B-C루프, C-D루프 또는 D-E루프에 융합된 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자와 결합 가능한 분자는 페리틴 단량체의 N-말단과 A 헬릭스 사이 또는 E 헬릭스와 C-말단 사이에 융합된 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자와 결합 가능한 분자는 페리틴 단량체의 α-헬릭스 내부에 융합된 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자와 결합 가능한 분자는 페리틴 단량체의 A 헬릭스, B 헬릭스, C 헬릭스, D 헬릭스 또는 E 헬릭스 내부에 융합된 약학 조성물.
- 청구항 1에 있어서, 상기 단백질은 인간 트랜스페린 수용체에 대한 결합력이 떨어지도록 돌연 변이된 것인 약학 조성물.
- 청구항 1에 있어서, 상기 단백질을 구성하는 페리틴 단량체 중 적어도 하나가 서열번호 1의 서열에서 15번, 16번, 23번, 82번, 84번, 117번, 120번, 또는 124번 아미노산이 알라닌, 글라이신, 발린 또는 류신으로 치환된 것인 약학 조성물.
- 청구항 1에 있어서, 트랜스페린 수용체에 대한 결합력(K)이 다음 수학식 1을 만족하는 약학 조성물:[수학식 1]K ≥ 10 nM(식 중, K [P][T]/[PT]이고, 여기서 [P]는 상기 단백질과 상기 트랜스페린 수용체와의 결합 반응의 평형 상태에서의 상기 단백질의 농도를 나타내고, [T]는 상기 평형 상태에서의 상기 트랜스페린 수용체의 농도를 나타내며, [PT]는 상기 평형 상태에서의 상기 단백질과 상기 트랜스페린 수용체의 복합체의 농도를 나타냄).
- 청구항 10에 있어서, 상기 트랜스페린 수용체는 인간 트랜스페린 수용체인 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자는 Her-2/neu, VISTA, 4-1BBL, Galectin-9, Adenosine A2a receptor, CD80, CD86, ICOS, ICOSL, BTLA, OX-40L, CD155, BCL2, MYC, PP2A, BRD1, BRD2, BRD3, BRD4, BRDT, CBP, E2F1, MDM2, MDMX, PPP2CA, PPM1D, STAT3, IDH1, PD1, CTLA4, PD-L1, PD-L2, LAG3, TIM3, TIGIT, BTLA, SLAMF7, 4-1BB, OX-40, ICOS, GITR, ICAM-1, BAFFR, HVEM, LFA-1, LIGHT, NKG2C, SLAMF7, NKp80, LAIR1, 2B4, CD2, CD3, CD16, CD20, CD27, CD28, CD40L, CD48, CD52, EGFR family, AXL, CSF1R, DDR1, DDR2, EPH receptor family, FGFR family, VEGFR family, IGF1R, LTK, PDGFR family, RET, KIT, KRAS, NTRK1 및 NTRK2으로 이루어진 군에서 선택되는 어느 하나인 약학 조성물.
- 청구항 1에 있어서, 상기 면역 관문 분자와 결합 가능한 분자는 상기 면역 관문 분자에 대해 결합력이 있는 리간드 또는 리간드의 단편, 수용체 또는 수용체의 단편, 항체 또는 항원 결합부위(CDR)를 포함하는 항체의 단편인 약학 조성물.
- 청구항 1에 있어서, 상기 페리틴은 인간 페리틴 중쇄인 약학 조성물.
- 청구항 1에 있어서, 항암제를 더 포함하거나, 항암제와 병용투여되는 약학 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280032816.5A CN117255690A (zh) | 2021-05-03 | 2022-05-03 | 用于预防或治疗肺癌的药物组合物 |
EP22799102.3A EP4335450A1 (en) | 2021-05-03 | 2022-05-03 | Pharmaceutical composition for prevention or treatment of lung cancer |
JP2023568032A JP2024517832A (ja) | 2021-05-03 | 2022-05-03 | 肺癌の予防または治療用薬学組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0057060 | 2021-05-03 | ||
KR20210057060 | 2021-05-03 | ||
KR1020220054781A KR20220150221A (ko) | 2021-05-03 | 2022-05-03 | 폐암의 예방 또는 치료용 약학 조성물 |
KR10-2022-0054781 | 2022-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022235059A1 true WO2022235059A1 (ko) | 2022-11-10 |
Family
ID=83932876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006352 WO2022235059A1 (ko) | 2021-05-03 | 2022-05-03 | 폐암의 예방 또는 치료용 약학 조성물 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2024517832A (ko) |
WO (1) | WO2022235059A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150088597A (ko) * | 2014-01-24 | 2015-08-03 | 국립대학법인 울산과학기술대학교 산학협력단 | 항원 펩타이드-페리틴 융합단백질 및 이를 포함하는 백신 조성물 |
KR20170027683A (ko) * | 2015-09-02 | 2017-03-10 | 경북대학교 산학협력단 | 인간 유래 페리틴 모노머 단편 및 이를 이용한 융합폴리펩티드 |
KR20170047120A (ko) * | 2015-10-22 | 2017-05-04 | 고려대학교 산학협력단 | 암 특이적 에피토프와 연결된 단백질 나노입자 및 이를 포함하는 암 면역치료용 조성물 |
KR20180008353A (ko) * | 2016-07-15 | 2018-01-24 | 한국과학기술연구원 | 신규 나노케이지 및 그의 용도 |
-
2022
- 2022-05-03 JP JP2023568032A patent/JP2024517832A/ja active Pending
- 2022-05-03 WO PCT/KR2022/006352 patent/WO2022235059A1/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150088597A (ko) * | 2014-01-24 | 2015-08-03 | 국립대학법인 울산과학기술대학교 산학협력단 | 항원 펩타이드-페리틴 융합단백질 및 이를 포함하는 백신 조성물 |
KR20170027683A (ko) * | 2015-09-02 | 2017-03-10 | 경북대학교 산학협력단 | 인간 유래 페리틴 모노머 단편 및 이를 이용한 융합폴리펩티드 |
KR20170047120A (ko) * | 2015-10-22 | 2017-05-04 | 고려대학교 산학협력단 | 암 특이적 에피토프와 연결된 단백질 나노입자 및 이를 포함하는 암 면역치료용 조성물 |
KR20180008353A (ko) * | 2016-07-15 | 2018-01-24 | 한국과학기술연구원 | 신규 나노케이지 및 그의 용도 |
Non-Patent Citations (2)
Title |
---|
"GenBank", Database accession no. NM_002032 |
MONTEMIGLIO LINDA CELESTE, TESTI CLAUDIA, CECI PIERPAOLO, FALVO ELISABETTA, PITEA MARTINA, SAVINO CARMELINDA, ARCOVITO ALESSANDRO,: "Cryo-EM structure of the human ferritin–transferrin receptor 1 complex", NATURE COMMUNICATIONS, vol. 10, no. 1, 1 December 2019 (2019-12-01), XP093000685, DOI: 10.1038/s41467-019-09098-w * |
Also Published As
Publication number | Publication date |
---|---|
JP2024517832A (ja) | 2024-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019229076B2 (en) | Anti-TIGIT antibodies and uses thereof | |
KR102309950B1 (ko) | 체크포인트 억제제 이중특이적 항체 | |
US11305011B2 (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
JP2022541349A (ja) | Mage-aに特異的に結合する抗原結合タンパク質 | |
AU2018271751B2 (en) | Anti-human interleukin-2 antibodies and uses thereof | |
WO2017030370A1 (ko) | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 | |
AU2017206656A1 (en) | Immunopotentiator enhanced superantigen mediated cancer immunotherapy | |
US20210032370A1 (en) | Recruiting agent further binding an mhc molecule | |
IL265834B (en) | hla-restricted vgll1 peptides and their use | |
WO2021102624A1 (en) | Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx) | |
WO2018199593A1 (ko) | Her3 및 cd3에 결합하는 이중특이적 항체 | |
WO2018186706A1 (ko) | Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물 | |
US20230132241A1 (en) | Antigen binding proteins specifically binding prame | |
WO2022235059A1 (ko) | 폐암의 예방 또는 치료용 약학 조성물 | |
US20230357428A1 (en) | Antigen binding proteins specifically binding prame | |
CN112204048A (zh) | 抗cct5结合分子及其使用方法 | |
US20230192903A1 (en) | Bispecific antibody against cldn18.2 and cd3 | |
WO2022235061A1 (ko) | 신규 단백질 | |
CN110115758B (zh) | Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用 | |
KR20220150221A (ko) | 폐암의 예방 또는 치료용 약학 조성물 | |
WO2023195805A2 (ko) | Itgb2 매개 약물전달체 | |
WO2022092974A1 (ko) | 항체 유사 단백질 및 그 용도 | |
WO2021086159A1 (ko) | 면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도 | |
WO2021086158A1 (ko) | 질환 항원이 융합된 단백질 및 이의 용도 | |
WO2019066536A1 (ko) | 신규 암 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22799102 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18289152 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023568032 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280032816.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022799102 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022799102 Country of ref document: EP Effective date: 20231204 |